Hillsdale Investment Management Inc. acquired a new position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report) in the fourth quarter, HoldingsChannel reports. The fund acquired 308,200 shares of the company’s stock, valued at approximately $7,976,000.
Other institutional investors have also made changes to their positions in the company. Doma Perpetual Capital Management LLC grew its stake in shares of Pacira BioSciences by 49.7% during the third quarter. Doma Perpetual Capital Management LLC now owns 2,701,324 shares of the company’s stock worth $69,613,000 after purchasing an additional 897,255 shares during the period. Impax Asset Management Group plc grew its stake in shares of Pacira BioSciences by 25.0% during the fourth quarter. Impax Asset Management Group plc now owns 750,027 shares of the company’s stock worth $19,411,000 after purchasing an additional 150,000 shares during the period. Assenagon Asset Management S.A. grew its stake in shares of Pacira BioSciences by 87.3% during the fourth quarter. Assenagon Asset Management S.A. now owns 435,143 shares of the company’s stock worth $11,262,000 after purchasing an additional 202,773 shares during the period. Hennion & Walsh Asset Management Inc. grew its stake in shares of Pacira BioSciences by 171.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 138,105 shares of the company’s stock worth $3,574,000 after purchasing an additional 87,210 shares during the period. Finally, Gagnon Securities LLC grew its stake in shares of Pacira BioSciences by 22.1% during the third quarter. Gagnon Securities LLC now owns 449,717 shares of the company’s stock worth $11,589,000 after purchasing an additional 81,364 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.
Pacira BioSciences Stock Performance
PCRX stock opened at $23.22 on Friday. The business’s 50-day moving average price is $23.58 and its two-hundred day moving average price is $23.33. The company has a current ratio of 4.73, a quick ratio of 3.35 and a debt-to-equity ratio of 0.56. The firm has a market cap of $913.66 million, a PE ratio of 193.52 and a beta of 0.32. Pacira BioSciences, Inc. has a 1-year low of $18.80 and a 1-year high of $27.64.
Analysts Set New Price Targets
A number of equities research analysts recently commented on the company. Royal Bank Of Canada lifted their price objective on Pacira BioSciences from $22.00 to $24.00 and gave the stock a “sector perform” rating in a research note on Friday, May 1st. Weiss Ratings raised Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Wednesday, May 20th. Wall Street Zen lowered Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 28th. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Finally, Needham & Company LLC lifted their target price on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Friday, May 1st. Three investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Pacira BioSciences currently has a consensus rating of “Hold” and a consensus target price of $29.40.
Get Our Latest Research Report on Pacira BioSciences
Insider Activity
In other Pacira BioSciences news, insider Jonathan Slonin sold 3,261 shares of Pacira BioSciences stock in a transaction dated Tuesday, March 17th. The stock was sold at an average price of $22.82, for a total transaction of $74,416.02. Following the transaction, the insider directly owned 223,640 shares in the company, valued at approximately $5,103,464.80. The trade was a 1.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Shawn Cross sold 12,941 shares of Pacira BioSciences stock in a transaction dated Thursday, April 23rd. The stock was sold at an average price of $25.16, for a total value of $325,595.56. Following the transaction, the chief financial officer owned 105,341 shares in the company, valued at approximately $2,650,379.56. This represents a 10.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 28,261 shares of company stock worth $702,610. Corporate insiders own 6.40% of the company’s stock.
Pacira BioSciences Profile
Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.
In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.
Featured Stories
- Five stocks we like better than Pacira BioSciences
- Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys
- Salesforce Stock Finds Support as AI Momentum Builds
- Dollar Tree Keeps Winning After Family Dollar Divorce
- Apple’s Agentic AI Plans Could Be Its Biggest Growth Story Yet
Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira BioSciences, Inc. (NASDAQ:PCRX – Free Report).
Receive News & Ratings for Pacira BioSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira BioSciences and related companies with MarketBeat.com's FREE daily email newsletter.
